Research Overview: Apcalis SX Oral Jelly 20 mg
Apcalis SX Oral Jelly 20 mg is a tadalafil citrate-based pharmaceutical compound manufactured by Ajanta Pharma for in-vitro laboratory research applications. This oral jelly formulation enables researchers to investigate the pharmacological properties and bioavailability characteristics of tadalafil citrate in controlled laboratory environments. The compound represents a generic formulation designed for comparative pharmaceutical research studies.
Tadalafil citrate functions as a selective phosphodiesterase type 5 (PDE5) inhibitor, making it valuable for researchers examining vascular smooth muscle relaxation mechanisms and cyclic guanosine monophosphate (cGMP) signalling pathways. The oral jelly presentation offers unique absorption characteristics for pharmacokinetic analysis compared to traditional tablet formulations. Laboratory researchers at Stroid UK Shop utilise this compound to study PDE5 enzymatic inhibition patterns and cellular response mechanisms.
The Ajanta Pharma manufacturing provides standardised quality control parameters essential for reproducible research outcomes. This formulation enables comparative studies alongside other tadalafil citrate research compounds available for laboratory investigation. Researchers examining vascular biology often incorporate this compound into studies investigating endothelial function and nitric oxide pathway modulation.
Laboratory Research Applications
Research teams investigate Apcalis SX Oral Jelly 20 mg to examine PDE5 inhibition kinetics and downstream cellular signalling cascades. The compound enables analysis of smooth muscle cell responses and vascular relaxation mechanisms in controlled experimental conditions. Pharmaceutical researchers study the oral jelly formulation’s dissolution characteristics and absorption profiles for bioavailability assessments.
Comparative studies utilise this compound alongside other research chemicals from our SARM collections and peptide research lines to examine different therapeutic pathways. Laboratory teams analyse the compound’s interaction with cellular phosphodiesterase enzymes and evaluate its effects on intracellular cGMP concentrations. Pharmacological research incorporates this formulation to study dose-response relationships and mechanism-of-action profiles.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Tadalafil Citrate |
| Concentration | 20 mg per sachet |
| Formulation | Oral Jelly |
| Manufacturer | Ajanta Pharma |
| CAS Number | Verify with supplier |
| Molecular Formula | Verify with supplier |
| Storage Conditions | Room temperature, dry environment |
| Shelf Life | As per manufacturer specifications |
Research Compliance Statement
Apcalis SX Oral Jelly 20 mg is supplied exclusively for in-vitro laboratory research purposes and pharmaceutical analysis studies. This compound is not intended for human consumption, clinical use, or therapeutic applications. Researchers must maintain appropriate laboratory safety protocols and waste disposal procedures when handling this research material. All investigations must comply with institutional research guidelines and applicable regulatory frameworks governing pharmaceutical research compounds.
